Genotypic and Phenotypic Characteristics of 29 Patients With Rare Types of Osteogenesis Imperfecta: Average 5 Years of Follow-Up.

Genotypic and Phenotypic Characteristics of 29 Patients With Rare Types of Osteogenesis Imperfecta: Average 5 Years of Follow-Up.
复制标题

29 名罕见类型成骨不全患者的基因型和表型特征:平均 5 年随访。

DOI:
10.3389/fgene.2021.622078
复制
发表时间:
2021
影响因子:
3.7
通讯作者:
Zhang ZL
Zhang ZL
中科院分区:
生物学3区
文献类型:
--
作者:
Xi L;Zhang H;Zhang ZL

文献摘要

参考文献

相似文献

成骨不全症(OI)是一种罕见的遗传性疾病,其特征为骨骼脆弱和结缔组织异常。90%的成骨不全症患者是由COL1A1和COL1A2的两种突变引起的,需要更多的研究来更好地了解罕见类型的成骨不全症。我们对29例罕见类型成骨不全症患者进行了平均5.4年的随访,记录了基因型、身高、骨密度(BMD)、血液生化指标、误诊情况和骨折情况。在18例患者(62.1%)中发现了IFITM5基因突变,这是中国人群中罕见类型成骨不全症最常见的致病基因。13例患者曾被误诊,初始误诊率为44.8%(13/29)。临床医生和医疗服务提供者应重视较高的误诊率,我们也给出了相应的建议。与未使用双膦酸盐治疗组相比,使用双膦酸盐治疗的患者腰椎骨密度更高,骨折更少,β - CTX和骨钙素水平更低。然而,V型成骨不全症患者和非V型患者之间没有显著差异。我们的研究丰富了对罕见类型成骨不全症患者基因型和表型特征以及双膦酸盐治疗的认识。
Osteogenesis imperfecta (OI) is a rare genetic disorder characterized by bone fragility and abnormal connective tissue. Ninety percent of OI patients are caused by two mutations of COL1A1 and COL1A2, and more investigation was needed to better understand the rare types of OI. We followed up 29 patients with rare types of OI for an average of 5.4 years, and genotype, height, bone mineral density (BMD), blood biochemical indexes, misdiagnosis, and fracture were recorded. IFITM5 gene mutation was found in 18 patients (62.1%), which represents the most common pathogenic gene of rare types of OI in Chinese population. Thirteen cases had once been misdiagnosed, and the initial misdiagnosis rate was 44.8% (13/29). The higher misdiagnosis rate should be paid attention to by clinicians and healthcare providers, and we also give corresponding suggestions. Compared with the non-bisphosphonate treatment group, patients treated with bisphosphonates had higher lumbar spine BMD, fewer fractures, and lower levels of β-CTX and osteocalcin. However, there was no significant difference between OI type V patients and non-type V patients. Our study enriched the knowledge of genotype and phenotype characteristics of OI patients with rare types and bisphosphonate therapy.
DOI: 10.1002/ajmg.a.61366
发表时间: 2019-10-21
影响因子: 2
作者:
Mortier, Geert R.;Cohn, Daniel H.;Warman, Matthew L.
通讯作者: Warman, Matthew L.
DOI: 10.3389/fgene.2020.00984
发表时间: 2020
影响因子: 3.7
作者:
Li S;Cao Y;Wang H;Li L;Ren X;Mi H;Wang Y;Guan Y;Zhao F;Mao B;Yang T;You Y;Guan X;Yang Y;Zhang X;Zhao X
通讯作者: Zhao X
DOI: 10.1016/j.bone.2016.02.018
发表时间: 2016-05-01
期刊: BONE
影响因子: 4.1
作者:
Sato, Atsuko;Ouellet, Jean;Rauch, Frank
通讯作者: Rauch, Frank
DOI: 10.1016/j.ajhg.2019.08.008
发表时间: 2019-10-03
影响因子: 9.8
作者:
Moosa, Shahida;Yamamoto, Guilherme L.;Netzer, Christian
通讯作者: Netzer, Christian
四个不相关的中国成骨不全家系中 WNT1、TMEM38B、P4HB 和 PLS3 基因的新突变
DOI: 10.4158/ep-2018-0443
发表时间: 2019-03-01
期刊: ENDOCRINE PRACTICE
影响因子: 4.2
作者:
Cao, Yang-Jia;Zhang, Hao;Zhang, Zhen-Lin
通讯作者: Zhang, Zhen-Lin